Dave Cole, Head of Research, Accession Therapeutics, introduces a replicating viral platform for systemic tumour targeting. Cancer immunotherapy has transformed oncology. Immune checkpoint inhibitors and cell therapies have shown that the immune system can be mobilised to achieve durable tumour control. Yet for most patients, response rates remain modest. Many… Read More
Trial results have revealed encouraging results for a new vaccine targeting group B meningococcus (MenB) and established that a gene-based vaccine platform can induce protective antibody responses against bacteria. The investigational vaccine, ChAdOx1 MenB.1, developed by researchers at the University of Oxford, was shown to be safe… Read More
A new Case Study is now available to download from Hamilton. Oxford Biomedica is an innovative leading viral vector specialist focused on delivering life-changing therapies to patients. The company works across key viral vector delivery systems (lentiviral-, adeno-associated viral- and adenoviral-based vector systems), providing innovative solutions to cell and gene… Read More
In this Case Study, Oxford Biomedica, an innovative global gene and cell therapy company, describes: The automated system used for a 10-day cell-based workflow required for an analytical test to determine viral vector titer The advantages of Hamilton’s CECULA Graphical User Interface (GUI) for the planning of long-term cell-based assays… Read More
Biotechnology company Circio Holding has secured approximately NOK 10.7 million (€907.4k) in financing to support the development of its circVec circular mRNA technology. The major allocations in the financing were to existing shareholders Høse AS and Bækkelaget Holding AS, and new shareholders Star Kapital AS (v/ Tom A Thorsen) and… Read More
Dr Andrea O'Hara, Senior Product Manager at Azenta Life Sciences asks why integration site analysis (ISA) is critical for the safety and efficacy of viral vectors for gene therapy. Cell and gene therapies have revolutionised how clinicians treat a variety of diseases including cancer, blindness, and metabolic disorders. With these… Read More
Over the three days of Advanced Therapies Week (ATW) 2024 in Miami, Florida, US, 16-19 January 2024, DDW’s Megan Thomas heard from attendees about the obstacles the sector needs to overcome to succeed. Viral vector manufacturing At the Advanced Therapies Awards ceremony, Dr Luigi Naldini, Director of the San Raffaele… Read More
